Healthcare Delivery Innovation Center, Minneapolis Heart Institute, 920 East 28th Street, Suite 300, Minneapolis, MN, 55407, USA.
Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA.
Sci Rep. 2021 Jul 23;11(1):15097. doi: 10.1038/s41598-021-94203-7.
There is little data describing trends in the use of hydroxychloroquine for COVID-19 following publication of randomized trials that failed to demonstrate a benefit of this therapy. We identified 13,957 patients admitted for active COVID-19 at 85 U.S. hospitals participating in a national registry between March 1 and August 31, 2020. The overall proportion of patients receiving hydroxychloroquine peaked at 55.2% in March and April and decreased to 4.8% in May and June and 0.8% in July and August. At the hospital-level, median use was 59.4% in March and April (IQR 48.5-71.5%, range 0-100%) and decreased to 0.3% (IQR 0-5.4%, range 0-100%) by May and June and 0% (IQR 0-1.3%, range 0-36.4%) by July and August. The rate and hospital-level uniformity in deimplementation of this ineffective therapy for COVID-19 reflects a rapid response to evolving clinical information and further study may offer strategies to inform deimplementation of ineffective clinical care.
在随机试验未能证明该疗法有益之后，发表了有关羟氯喹治疗 COVID-19 的趋势的数据很少。我们在 2020 年 3 月 1 日至 8 月 31 日期间，在美国 85 家医院参与的国家登记处中，确定了 13957 名患有活动性 COVID-19 的患者。接受羟氯喹治疗的患者总体比例在 3 月和 4 月达到 55.2％的峰值，然后在 5 月和 6 月降至 4.8％，7 月和 8 月降至 0.8％。在医院层面，3 月和 4 月的中位数使用率为 59.4％（IQR 48.5-71.5％，范围 0-100％），到 5 月和 6 月降至 0.3％（IQR 0-5.4％，范围 0-100％），到 7 月和 8 月降至 0％（IQR 0-1.3％，范围 0-36.4％）。这种对 COVID-19 无效治疗方法的快速停用，反映了对不断变化的临床信息的快速响应，进一步的研究可能会提供策略，为无效临床护理的停用提供信息。
